Acadia Pharmaceuticals Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ACAD, updated each market day.
ACAD AI Sentiment
AI sees no strong directional signal for Acadia Pharmaceuticals Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Sector
Exchange
Market Cap
$3,848,063,415
Cap Tier
Employees
798
Headquarters
SAN DIEGO, CA
Listed Since
May 27, 2004
Website
ACAD Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ACAD Volatility
Acadia Pharmaceuticals Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
